Adverse reactions and events related to musculoskeletal allografts: reviewed by the World Health Organisation Project NOTIFY
- 3 November 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in International Orthopaedics
- Vol. 36 (3), 633-641
- https://doi.org/10.1007/s00264-011-1391-7
Abstract
The use of bone and connective tissue allografts has grown rapidly and surpassed the use of autografts in many countries. Being of human origin, bone and tendon allografts carry the risk of disease transmission and complications have been reported. As part of the Project NOTIFY led by the World Health Organisation, an effort to improve recognition, reporting, tracking and investigation of adverse outcomes of allografts was initiated, achieving a comprehensive review of associated disease transmission and failures. Those involving the use of musculoskeletal allografts are reported here. A major objective is to involve orthopaedic surgeons in the improvement of the safe use of the musculoskeletal allografts. We reviewed the medical literature, requested reports from surgeons in selected professional organisations and informally surveyed tissue bank organisations and selected tissue bank professionals to discover reported and unreported cases of adverse outcomes. We analysed each case to decide the likelihood that the complication was truly allograft related. The efficiency of the procedures involved in bone banking and bone and tendon allograft has improved significantly during the last three decades. The evolution of the incidence of reported adverse reactions and events reflects positively on the safety of transplanted tissues. Cases of bacterial and viral transmission by bone and tendon allografts occurred mainly with those that contained viable cells, were not processed to remove cells, or were not disinfected or sterilised. We documented cases of transmission of human immunodeficiency virus (HIV), hepatitis C virus (HCV), human T-lymphotropic virus (HTLV), unspecified hepatitis, tuberculosis and other bacteria. Reporting of these adverse outcomes has led to corrective actions and has significantly improved the safety of allograft use. However, it is probable that not all cases have been reported and investigated. Considering the high quality standards achieved in many countries, the best approach for further improvement in the safety of allografts is through a systematic reporting of all serious adverse reactions and events in the context of a global biovigilance programme.Keywords
This publication has 60 references indexed in Scilit:
- Reported infections after human tissue transplantation before and after new food and drug administration (FDA) regulations, United States, 2001 through June, 2010Cell and Tissue Banking, 2011
- Coding and traceability for cells, tissues and organs for transplantationCell and Tissue Banking, 2010
- Tissue donation and virus safety: more nucleic acid amplification testing is neededTransplant Infectious Disease, 2010
- B-cell Lymphoma in retrieved femoral heads: a long term follow upBMC Musculoskeletal Disorders, 2009
- Bacterial infection transmitted by human tissue allograft transplantationCell and Tissue Banking, 2006
- Clinical effectiveness of processed and unprocessed boneTransfusion Medicine, 2005
- Probable Creutzfeldt-Jakob disease after a cadaveric dural graftEuropean Journal of Epidemiology, 1995
- A Comprehensive Study of Physical Parameters, Biomechanical Properties, and Statistical Correlations of Iliac Crest Bone Wedges Used in Spinal Fusion SurgerySpine, 1994
- Transmission of Creutzfeldt-Jakob Disease by Dural Cadaveric GraftJournal of Neurosurgery, 1989
- Biomechanical Properties of Bone AllograftsClinical Orthopaedics and Related Research, 1983